ArticleCancer immunology, immunotherapy : CII2024

DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy.

Zhe Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.